Pay in 4 interest-free payments of $7.21 Learn more
Ships within 48 hours · Estimated delivery Sep 23 - Sep 28
In this updated module, GP Dr Pipin Singh reviews these and other key changes to the guideline
This guidance advised that companies should show that the risk of cardiovascular events in T2DM patients didnt increase with the use of their new antidiabetic therapies (drugs or therapeutic biologics), a proactive response to concerns about the cardiovascular safety of some diabetes medications developed previously ( accessed August 25, 2025)
Merck said the addition to its GLP-1 arsenal is to provide additional cardiometabolic benefits beyond weight reduction. BioWorld Asia Deals and M&A Cardiovascular Small molecule Asia-Pacific China
Diabetes 49:11561164 Smrcka AV, Brown JH, Holz GG (2012) Role of phospholipase C in physiological phosphoinositide signaling networks
